Acepodia, Inc. (TPEX:6976)
Taiwan
· Delayed Price · Currency is TWD 14.90
-0.35 (-2.30%)
At close: Dec 5, 2025
Acepodia Company Description
Acepodia, Inc. operates as a clinical stage biotechnology company.
The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care.
It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; ACE 2016 targeting EGFR, which is in Phase 1 clinical trial; ACE183 that is in phase 1 clinical trial.
Acepodia Inc. has strategic clinical collaboration with Pfizer Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases.
The company is based in Grand Cayman, the Cayman Islands.
Acepodia, Inc.
| Country | Cayman Islands |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Shih-Chia Hsiao |
Contact Details
Address: Ugland House Grand Cayman, KY1-1104 Cayman Islands | |
| Website | acepodia.com |
Stock Details
| Ticker Symbol | 6976 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | KYG0073G1091 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shih-Chia Hsiao Ph.D. | Co-Founder, Chief Executive Officer, President and Chairman |
| Dr. Yuhmin Yang Ph.D. | Co-Founder and Advisor |
| Ray Wu M.B.A. | Executive Director of Finance |
| YanDa Lai | Director of Operations |
| Yajun Wang Ph.D. | Chief Technical Officer |
| Jessica Lee M.B.A., M.S. | Head of Business Development |
| Dr. Arthur Foo Ph.D. | Head of Clinical operation |
| Stephanie Hsiao | Secretary |